# Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

> **NCT02639247** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 333 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** SOF/VEL/VOX
- **DRUG:** SOF/VEL

## Key facts

- **NCT ID:** NCT02639247
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-23
- **Primary completion:** 2016-10-05
- **Final completion:** 2017-01-18
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2019-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02639247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02639247, "Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02639247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*